Investigators reviewed medical records from January 1, 2020, through December 31, 2023, at a peri-urban referral hospital in Kiambu County (facility name redacted in the source). The cohort travelled a median distance of 47.8 kilometres to reach the facility. That travel burden accompanied a median onset-to-presentation interval of 24 hours, a delay interval that far exceeds typical windows for emergency reperfusion interventions. Long distances. Long delays. Those facts alone constrain what any center can safely deliver.
Patients arriving after such delays will routinely be ineligible for time-dependent therapies. The study team framed these prehospital metrics as a primary contributor to low acute intervention rates but did not report granular timing relative to exact therapeutic cutoffs for individual patients. The records therefore document population-level delays without providing enough temporal detail to ascribe each missed therapy to late arrival versus in-hospital factors.
The authors assessed delivery of acute reperfusion treatments against the 2019 AHA/ASA Guidelines for early management of acute ischemic stroke. The facility had patients who presented within the therapeutic windows for intravenous alteplase and for thrombectomy, yet the report states these patients did not receive those treatments. The source did not provide counts of how many patients presented within the windows, nor did it list documented contraindications or operational reasons for withholding therapy.
This absence of reperfusion therapy occurred in a center without a dedicated stroke unit and with extended prehospital delays. The study did not describe internal stroke pathways, thrombolysis protocols, imaging availability, or in-hospital door-to-needle and door-to-groin metrics — details that would clarify whether system processes, supply issues, clinician decision-making, or patient factors were decisive. Investigators therefore reported a gap between guideline recommendations and practice, but the medical record review as presented leaves open multiple potential explanations.
The study team evaluated elements of secondary prevention at discharge. Among 86 ischemic stroke patients deemed eligible for antiplatelet therapy, 67 (77.9%) were discharged on antiplatelet medication (aspirin). That level of adherence is moderate; some patients left care without guideline-concordant antiplatelet therapy.
Statin prescribing at discharge was recorded for 123 patients, of whom 84 (68.3%) left on statin therapy. The source did not specify LDL values, the intensity of statin prescribed, or whether prescribers documented contraindications or patient refusal. These missing details limit interpretation: the numerical adherence rates are clear, but the clinical rationale behind nonprescription is not documented in the report.
Taken together, antiplatelet and statin discharge rates suggest partial uptake of secondary prevention measures. The authors positioned these findings as targets for focused quality-improvement interventions, particularly around discharge medication reconciliation, education, and follow-up systems.
The record review found no dedicated stroke unit at the facility. That structural deficit appeared in the investigators' account as a central barrier to delivering organized, guideline-concordant stroke care. Without a stroke unit, coordinated monitoring, standardized order sets, and concentrated nursing expertise are harder to maintain — systems elements that support timely reperfusion, blood pressure management, early rehabilitation assessment, and secondary prevention.
The source lists eight clinical practices that were evaluated against guideline standards but does not enumerate each practice in the text provided. The authors reported minimal overall adherence to evidence-based recommendations. The dataset lacks detail on staffing, imaging access, in-hospital workflow, or supply chains that could explain why reperfusion therapies were not performed even when patients reportedly arrived within treatment windows.
The investigators acknowledged that their review quantified the gap between recommended and actual practice at a single peri-urban referral facility. The source did not report counts of patients who arrived inside specific therapeutic time windows, nor did it provide reasons from clinical notes why alteplase or thrombectomy were withheld. Dosing information, precise timing metrics (door-to-needle, door-to-groin), and granular patient-level contraindication data were not included in the available report.
These omissions limit causal interpretation: the study documents a substantial implementation gap but cannot fully disentangle prehospital delay, resource constraints, clinician decision-making, or documented contraindications as proximate causes. The study authors framed their results as context-specific evidence to guide quality-improvement and guideline implementation efforts in similar resource-constrained settings. Remaining questions that the source leaves open include: how many patients truly met all eligibility criteria for reperfusion, what in-hospital processes impeded therapy delivery, and which targeted interventions would most effectively close the documented care gaps.
The report ends on those specific implementation uncertainties and the need for targeted facility-level audits and process-improvement initiatives rather than broad, synthetic conclusions about system transformation.